{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T12:48:11Z","timestamp":1791809291575,"version":"4.3.4"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T00:00:00Z","timestamp":1678060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Zhejiang Medical and Health Science and Technology","award":["2022KY844"],"award-info":[{"award-number":["2022KY844"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Ustekinumab (UST) was approved in China for moderate-to-severe Crohn\u2019s disease (CD) in 2020. The prevalence rates of tuberculosis and hepatitis B virus (HBV) infection are high in China, and no guideline clearly states that tuberculosis chemoprophylaxis or prophylactic anti-HBV therapy should be prescribed before UST administration. This study aimed to assess the risk of tuberculosis and HBV reactivation in CD patients with latent tuberculosis infection (LTBI) and previous HBV infection receiving UST.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A multicenter retrospective cohort study was carried out at 68 hospitals in China to assess 721 adult CD cases administered UST between May 1, 2020, and December 31, 2021. CD and concurrent LTBI or HBV carrier were included. Hepatitis B serology, T-SPOT.TB, and tuberculin skin tests were performed at baseline. The primary outcome was tuberculosis or HBV reactivation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Patients with CD-concomitant LTBI or who were HBV carriers receiving UST therapy were retrospectively enrolled from 15 hospitals in China. A total of 53 CD with LTBI patients and 17 CD with HBV carrier patients receiving UST were included. Treatment and follow-up durations were 50 \u00b1 20 weeks and 50 \u00b1 15 weeks in the LTBI and HBV carrier groups, respectively. A total of 25 CD patients with LTBI underwent chemoprophylaxis and 28 did not. A total of 11 HBV carriers had antiviral prophylaxis and 6 did not. No patient experienced tuberculosis or HBV reactivation or liver dysfunction during follow-up.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>UST was safe for treatment of CD because no patient developed tuberculosis, persistent hepatitis, or acute liver failure during therapy, whether with a prophylactic regimen or not, based on our sample size and limited follow-up time.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ibd\/izad032","type":"journal-article","created":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T14:01:36Z","timestamp":1678197696000},"page":"45-52","source":"Crossref","is-referenced-by-count":15,"title":["Risk of Tuberculosis and Hepatitis B Reactivation in Patients With Crohn\u2019s Disease on Ustekinumab: A Nationwide Real-World Study"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8667-8474","authenticated-orcid":false,"given":"Rongbei","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University , Hangzhou , China"},{"name":"Center of Inflammatory Bowel Disease, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University , Hangzhou , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhilun","family":"Li","sequence":"additional","affiliation":[{"name":"School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University , Nanjing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingna","family":"Ye","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University , Hangzhou , China"},{"name":"Center of Inflammatory Bowel Disease, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University , Hangzhou , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, First Affiliated Hospital of Anhui Medical University, Hefei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7611-7390","authenticated-orcid":false,"given":"Jian","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou , China"},{"name":"Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases , Guangzhou , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baili","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, First Affiliated Hospital of Sun Yat-sen University , Guangzhou , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuli","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, First Affiliated Hospital of Dalian Medical University , Dalian , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bei","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yubei","family":"Gu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Rui Jin Hospital, affiliate to Shanghai Jiao Tong University School of Medicine, Shanghai , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, First Affiliated Hospital of Soochow University, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunhui","family":"Ouyang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Second Xiangya Hospital, Central South University, Changsha, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomei","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Chongqing General Hospital , Chongqing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, First Hospital of Jilin University , Changchun , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyun","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Zhongshan Hospital, School of Medicine, Xiamen University , Xiamen , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haixia","family":"Ren","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Renmin Hospital of Wuhan University , Wuhan , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangru","family":"Zhu","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Union Hospital, Huazhong University of Science and Technology , Wuhan , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Zhongnan Hospital of Wuhan University , Wuhan , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyu","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, First Affiliated Hospital of Nanjing Medical University , Nanjing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University , Hangzhou , China"},{"name":"Center of Inflammatory Bowel Disease, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University , Hangzhou , China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,3,6]]},"reference":[{"issue":"6","key":"2024010523411612300_CIT0001","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.smim.2006.07.010","article-title":"Inborn errors of IL-12\/23- and IFN-gamma-mediated immunity: molecular, cellular, and clinical features","volume":"18","author":"Filipe-Santos","year":"2006","journal-title":"Semin Immunol."},{"issue":"3","key":"2024010523411612300_CIT0002","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.3892\/etm.2016.3548","article-title":"Risk of tuberculosis during infliximab therapy for inflammatory bowel disease, rheumatoid arthritis, and spondyloarthropathy: a meta-analysis","volume":"12","author":"Wang","year":"2016","journal-title":"Exp Ther Med"},{"issue":"15","key":"2024010523411612300_CIT0003","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent","volume":"345","author":"Keane","year":"2001","journal-title":"N Engl J Med."},{"issue":"11","key":"2024010523411612300_CIT0004","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1056\/NEJMra031087","article-title":"Hepatitis B virus infection--natural history and clinical consequences","volume":"350","author":"Ganem","year":"2004","journal-title":"N Engl J Med."},{"issue":"3","key":"2024010523411612300_CIT0005","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.semarthrit.2007.10.011","article-title":"Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection","volume":"38","author":"Carroll","year":"2008","journal-title":"Semin Arthritis Rheum."},{"issue":"3","key":"2024010523411612300_CIT0006","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/apt.16130","article-title":"Targeted versus universal tuberculosis chemoprophylaxis in 1968 patients with inflammatory bowel disease receiving anti-TNF therapy in a tuberculosis endemic region","volume":"53","author":"Ye","year":"2021","journal-title":"Aliment Pharmacol Ther."},{"issue":"2","key":"2024010523411612300_CIT0007","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.gtc.2020.01.001","article-title":"Global epidemiology of viral hepatitis","volume":"49","author":"Razavi","year":"2020","journal-title":"Gastroenterol Clin North Am."},{"issue":"6","key":"2024010523411612300_CIT0008","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.crohns.2013.12.013","article-title":"Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease","volume":"8","author":"Rahier","year":"2014","journal-title":"J Crohns Colitis"},{"issue":"1","key":"2024010523411612300_CIT0009","doi-asserted-by":"crossref","first-page":"4","DOI":"10.5217\/ir.2018.16.1.4","article-title":"Asian Organization for Crohn\u2019s and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: risk assessment","volume":"16","author":"Park","year":"2018","journal-title":"Intest Res"},{"issue":"1","key":"2024010523411612300_CIT0010","doi-asserted-by":"crossref","first-page":"17","DOI":"10.5217\/ir.2018.16.1.17","article-title":"Asian Organization for Crohn\u2019s and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 2: management","volume":"16","author":"Park","year":"2018","journal-title":"Intest Res"},{"issue":"20","key":"2024010523411612300_CIT0011","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N Engl J Med."},{"key":"2024010523411612300_CIT0012","doi-asserted-by":"crossref","first-page":"736149","DOI":"10.3389\/fphar.2021.736149","article-title":"Reasons and factors contributing to Chinese patients\u2019 preference for ustekinumab in Crohn\u2019s disease: a multicenter cross-sectional study","volume":"12","author":"Yao","year":"2021","journal-title":"Front Pharmacol."},{"issue":"3","key":"2024010523411612300_CIT0013","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.cgh.2021.02.025","article-title":"Five-year efficacy and safety of ustekinumab treatment in Crohn\u2019s disease: the IM-UNITI trial","volume":"20","author":"Sandborn","year":"2022","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"1","key":"2024010523411612300_CIT0014","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/ecco-jcc\/jjz110","article-title":"IM-UNITI: three-year efficacy, safety, and immunogenicity of ustekinumab treatment of Crohn\u2019s disease","volume":"14","author":"Hanauer","year":"2020","journal-title":"J Crohns Colitis."},{"issue":"5","key":"2024010523411612300_CIT0015","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1111\/j.1365-2133.2012.11142.x","article-title":"The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection","volume":"167","author":"Tsai","year":"2012","journal-title":"Br J Dermatol."},{"issue":"3","key":"2024010523411612300_CIT0016","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/bjd.12045","article-title":"Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical setting","volume":"168","author":"Navarro","year":"2013","journal-title":"Br J Dermatol."},{"issue":"6","key":"2024010523411612300_CIT0017","first-page":"366","article-title":"Consensus on biological agents in treating patients with inflammatory bowel disease","volume":"41","author":"Inflammatory Bowel Disease Quality Control Center, Inflammatory Bowel Disease Group, Chinese Society of Gastroenterology, Chinese Medical Association","year":"2021","journal-title":"Chin J Dig"},{"issue":"5","key":"2024010523411612300_CIT0018","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.jaad.2019.12.033","article-title":"Ustekinumab does not increase tuberculosis risk: results from a national database in South Korea","volume":"82","author":"Cho","year":"2020","journal-title":"J Am Acad Dermatol."},{"issue":"3","key":"2024010523411612300_CIT0019","doi-asserted-by":"crossref","first-page":"e15274","DOI":"10.1111\/dth.15274","article-title":"Safety of therapies using ustekinumab in patients with psoriasis who have had hepatitis B virus infection","volume":"35","author":"K\u0142ujszo","year":"2022","journal-title":"Dermatol Ther."},{"key":"2024010523411612300_CIT0020","first-page":"J Heptatol","article-title":"EASL clinical practice guidelines: management of chronic hepatitis B virus infection","author":"European Association for the Study of the Liver","year":"2012"},{"key":"2024010523411612300_CIT0021","doi-asserted-by":"crossref","first-page":"2931402","DOI":"10.1155\/2018\/2931402","article-title":"Recent advances in HBV reactivation research","volume":"2018","author":"Guo","year":"2018","journal-title":"Biomed Res Int."},{"issue":"8","key":"2024010523411612300_CIT0022","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1111\/jgh.14648","article-title":"Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn\u2019s disease in Asia","volume":"34","author":"Ooi","year":"2019","journal-title":"J Gastroenterol Hepatol."},{"issue":"4","key":"2024010523411612300_CIT0023","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.crohns.2013.08.017","article-title":"Prevalence and factors related to hepatitis B and C infection in inflammatory bowel disease patients in China: a retrospective study","volume":"8","author":"Huang","year":"2014","journal-title":"J Crohns Colitis."},{"issue":"6","key":"2024010523411612300_CIT0024","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1097\/MD.0b013e3182380a76","article-title":"Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases","volume":"90","author":"P\u00e9rez-Alvarez","year":"2011","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"2024010523411612300_CIT0025","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.clinre.2016.10.005","article-title":"Role of interleukin-23 in monocyte-derived dendritic cells of HBV-related acute-on-chronic liver failure and its correlation with the severity of liver damage","volume":"41","author":"Bao","year":"2017","journal-title":"Clin Res Hepatol Gastroenterol."},{"issue":"9","key":"2024010523411612300_CIT0026","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s40261-018-0671-z","article-title":"Risk of hepatitis B reactivation in patients with psoriasis on ustekinumab","volume":"38","author":"Ting","year":"2018","journal-title":"Clin Drug Investig."}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article-pdf\/doi\/10.1093\/ibd\/izad032\/49432920\/izad032.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/30\/1\/45\/55119345\/izad032.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/30\/1\/45\/55119345\/izad032.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T23:46:18Z","timestamp":1704498378000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/30\/1\/45\/7070426"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,6]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,3,6]]},"published-print":{"date-parts":[[2024,1,5]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izad032","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,1,1]]},"published":{"date-parts":[[2023,3,6]]}}}